Home 2020 Wall Street’s Key Stock Analysts Research Report, All Buys

Wall Street’s Key Stock Analysts Research Report, All Buys


#stocks #bullish #buys #analysts #research #WallStreet


These are all Buys if you can manage the risk.

Daily HeffX-LTN reviews dozens of Wall Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. These reports cover stocks to buy

Below are our Buy calls for Tuesday, 3 November, as follows:

Clorox Co. (NYSE:CLX) was reiterated as Buy and its target price was raised to 268 from 263 at DA Davidson.

Genpact Ltd. (NYSE:G) was maintained as Buy but its price target was cut to 45 from 48 at Needham. The stock closed up 3.75% at 35.66 Monday and has a 47.22 consensus target price.

Hookipa Pharma Inc. (NASDAQ:HOOK) was started as Buy and a 21 price target at Truist Securities.

Kimco Realty Corp. (NYSE:KIM) was raised to Buy from Hold and its target price was raised to 14 from 12 at Truist Securities. It has a 13.36 consensus target price.

NICE Ltd. (NASDAQ: NICE) was started with a Buy rating and a $280 price objective at BofA Securities. The stock has a 239.27 consensus target price.

Have a healthy day, Keep the Faith!

Previous articleBritish Pound: GBP/USD (GBP=X) Technical Analysis and Charts with Metastock
Next articleFerrari (NYSE:RACE) on Pace to Mark the Top End of Full Year Guidance on All Metrics, the Stock is Running
Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he is the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.